HOLX Stock Summary and Trading Ideas (Hologic | NASDAQ:HOLX)

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic trades on the NASDAQ stock market under the symbol HOLX.

As of January 23, 2026, HOLX stock price declined to $75.05 with 1,825,545 million shares trading.

HOLX has a beta of 0.09, meaning it tends to be less sensitive to market movements. HOLX has a correlation of 0.00 to the broad based SPY ETF.

HOLX has a market cap of $16.73 billion. This is considered a Large Cap stock.

Last quarter Hologic reported $1 billion in Revenue and $1.13 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.03.

In the last 3 years, HOLX traded as high as $87.88 and as low as $51.90.

The top ETF exchange traded funds that HOLX belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.

HOLX has underperformed the market in the last year with a return of +5.4%, while the SPY ETF gained +14.9%. In the last 3 month period, HOLX fell short of the market, returning +1.5%, while SPY returned +3.5%. However, in the most recent 2 weeks HOLX has outperformed the stock market by returning +0.2%, while SPY returned 0.0%.

HOLX support price is $74.96 and resistance is $75.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOLX shares will trade within this expected range on the day.